| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/14/2010 | CN101693068A Medicament for lowering blood pressure and blood lipid |
| 04/14/2010 | CN101693062A Health-care product for reducing pressure and sugar and eliminating fat |
| 04/14/2010 | CN101693041A Transdermal zinc supplement |
| 04/14/2010 | CN101693034A Diffractive-ring mangiferin A in mango leaves and new application of mango leaf extractives containing diffractive-ring mangiferin A |
| 04/14/2010 | CN101692900A Natto seaweed capsule and preparation method thereof |
| 04/14/2010 | CN101259266B Preadipocyte heterologous vaccine and preparation method and application thereof |
| 04/13/2010 | USRE41226 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 04/13/2010 | US7696365 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors |
| 04/13/2010 | US7696234 Histamine H3 receptor agents, preparation and therapeutic uses |
| 04/13/2010 | US7696231 Therapy, prevention of metabolism disorders; insulin resistance; antidiabetic agents; hypoglycemic agents; anticholesterol agents; obesity; polycystic ovarian syndrome |
| 04/13/2010 | US7696212 1-[(phenanthridin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine; antiarthritic agents; obesity; antidiabetic agents; osteoporosis; dipeptidylpeptidase-IV (DPP-IV) inhibitors |
| 04/13/2010 | US7696181 Partial and full agonists of A1 adenosine receptors |
| 04/13/2010 | US7696172 culture product produced by culturing a recombinant host cell under suitable conditions to express the polypeptide; has an oncogenic activity; treating liver disorder cirrhosis, or pancreas disorder |
| 04/13/2010 | US7696162 Contains a surfactant and a preservative, an isotonicizing agent, a buffer, and/or an excipient; has less than 0.2% by weight of zinc based on the insulin content of the formulation; Polypeptide mixture; treating diabetes |
| 04/13/2010 | US7696161 Exendin agonist compounds |
| 04/13/2010 | US7696158 Use of IL-22 for the treatment of conditions of metabolic disorders |
| 04/13/2010 | US7696151 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity |
| 04/13/2010 | US7695720 target VEGFR2 (KDR/flk-1); for treating and preventing tumors |
| 04/13/2010 | CA2506993C Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
| 04/13/2010 | CA2443802C Pyrazolo[1,5-a]pyridines and medicines containing the same |
| 04/13/2010 | CA2432303C Pyrazole compounds useful as protein kinase inhibitors |
| 04/13/2010 | CA2430363C Compounds and their uses |
| 04/13/2010 | CA2422377C Pyrazole compounds useful as protein kinase inhibitors |
| 04/13/2010 | CA2399208C Nucleoside analogs with carboxamidine modified monocyclic base |
| 04/13/2010 | CA2363639C Covalently bridged insulin dimers |
| 04/13/2010 | CA2336807C Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 04/13/2010 | CA2102112C A substance for lowering high cholesterol level in serum and a method for preparing the same |
| 04/08/2010 | WO2010040055A2 Oral pharmaceutical formulations for antidiabetic compounds |
| 04/08/2010 | WO2010040054A2 Methods for suppressing toll-like receptor activity |
| 04/08/2010 | WO2010040012A1 Compositions and methods for reducing triglyceride levels |
| 04/08/2010 | WO2010039461A2 Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes |
| 04/08/2010 | WO2010039124A1 Benzenesulfonic acid salt compounds |
| 04/08/2010 | WO2010039040A1 Composition comprising a ppar agonist and a phospholipid component |
| 04/08/2010 | WO2010039019A1 Composition for promoting control of total and ldl cholesterol and/or weight loss and/or thermogenesis |
| 04/08/2010 | WO2010038901A1 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| 04/08/2010 | WO2010038842A1 Novel polyphenol compound |
| 04/08/2010 | WO2010038714A1 Lactic acid bacterium having high oxalic acid decomposition ability |
| 04/08/2010 | WO2010038690A1 Controlled release pharmaceutical composition |
| 04/08/2010 | WO2010038688A1 Particulate pharmaceutical composition for oral administration of atorvastatin |
| 04/08/2010 | WO2010038465A1 8-substituted isoquinoline derivative and use thereof |
| 04/08/2010 | WO2010037886A1 Chroman derivatives and uses thereof as inhibitors of the activity of decoupling proteins |
| 04/08/2010 | WO2010037256A1 Composition for reducing blood fat and blood glucose |
| 04/08/2010 | WO2010037255A1 The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation |
| 04/08/2010 | WO2010037225A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 04/08/2010 | WO2010037224A1 Method for preventing and treating cardiovascular diseases with brca1 |
| 04/08/2010 | WO2010006172A3 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs |
| 04/08/2010 | US20100087544 N, n -dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| 04/08/2010 | US20100087543 Pharmaceutical use of substituted amides |
| 04/08/2010 | US20100087541 Compounds for the treatment of metabolic disorders |
| 04/08/2010 | US20100087527 Curcumin Derivatives |
| 04/08/2010 | US20100087502 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders |
| 04/08/2010 | US20100087485 4-aminopiperidine derivatives |
| 04/08/2010 | US20100087481 Oral pharmaceutical formulations for antidiabetic compounds |
| 04/08/2010 | US20100087477 Selective glycosidase inhibitors |
| 04/08/2010 | US20100087475 Pharmaceutical compounds |
| 04/08/2010 | US20100087468 Modulators of ppar and methods of their preparation |
| 04/08/2010 | US20100087465 Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
| 04/08/2010 | US20100087464 Protein kinase inhibitors and methods for using thereof |
| 04/08/2010 | US20100087449 Heteroarylamide pyrimidone compounds |
| 04/08/2010 | US20100087430 Novel benzofuran potassium channel blockers and uses thereof |
| 04/08/2010 | US20100087418 Benzoxazepine derivatives and use thereof |
| 04/08/2010 | US20100087414 Method and intermediates for the preparation of derivatives of n (1-benzhydrylazetidin-3-yl)-n-phenylmethylsulfonamide |
| 04/08/2010 | US20100087400 Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof |
| 04/08/2010 | US20100087396 Novel Compounds Having Selective Inhibiting Effect at GSK3 |
| 04/08/2010 | US20100087380 Pharmaceutical compositions for inhibiting intestinal permeability |
| 04/08/2010 | US20100087367 Products and methods using soy peptides to lower total and ldl cholesterol levels |
| 04/08/2010 | US20100087366 Gh secretagogues and uses thereof |
| 04/08/2010 | US20100087365 Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof |
| 04/08/2010 | US20100087360 Heterocycle-substituted benzimidazole derivative |
| 04/08/2010 | US20100087359 Use of tryptophan rich peptides |
| 04/08/2010 | US20100086619 Dietary supplement containing strontium (M) ascorbate, compositions containing same, method for making same and method for using same |
| 04/08/2010 | US20100086609 Methods and Compositions for Delivering Peptides |
| 04/08/2010 | US20100086596 Microspheres for releasing an octreotide compound without an initial time lag |
| 04/08/2010 | US20100086565 Vectors for expression of hml-2 polypeptides |
| 04/08/2010 | US20100086531 METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND Nrf2 TRANSCRIPTION FACTORS |
| 04/08/2010 | CA2740342A1 Pharmaceutical composition for modified release |
| 04/08/2010 | CA2739513A1 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| 04/08/2010 | CA2739418A1 Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes |
| 04/08/2010 | CA2739345A1 Lactic acid bacterium having high oxalic acid decomposition ability |
| 04/08/2010 | CA2739083A1 Methods for suppressing toll-like receptor activity |
| 04/08/2010 | CA2738563A1 8-substituted isoquinoline derivatives and the use thereof |
| 04/08/2010 | CA2738348A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 04/07/2010 | EP2172560A2 stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 04/07/2010 | EP2172479A1 Glp-1 peptide having sugar chain attached thereto |
| 04/07/2010 | EP2172468A1 Benzimidazolone compounds |
| 04/07/2010 | EP2172453A1 COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY |
| 04/07/2010 | EP2172452A1 Preparation of crystalline atorvastatin magnesium |
| 04/07/2010 | EP2172447A1 Amide compound |
| 04/07/2010 | EP2172246A2 Methods for Alzheimer's disease treatment and cognitive enhancement |
| 04/07/2010 | EP2172207A1 A pharmaceutical composition for treating diabetes and its process for preparation |
| 04/07/2010 | EP2172206A1 The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof |
| 04/07/2010 | EP2172204A1 Methods of treating syndrome X with apliphatic polyamines |
| 04/07/2010 | EP2172195A1 Cholesterol-control agent |
| 04/07/2010 | EP2172116A1 Rice bran-like composition and food |
| 04/07/2010 | EP2170905A2 Sirtuin modulating thiazolopyridine compounds |
| 04/07/2010 | EP2170883A1 Substituted fused pyrimidines as antagonists of gpr105 activity |
| 04/07/2010 | EP2170864A1 Pyridone gpr119 g protein-coupled receptor agonists |
| 04/07/2010 | EP2170852A1 1, 3 - dihydroxy substituted phenylamide glucokinase activators |
| 04/07/2010 | EP2170847A2 Substituted piperazines as cb1 antagonists |
| 04/07/2010 | EP2170846A2 Substituted piperazines as cb1 antagonists |